The GLP-1 market is best served by offering oral and injectable formulations
As GLP-1 therapies shift from injectable to oral dosage forms, overcoming bioavailability and solubility challenges has become a central development priority. Emerging onto the scene are strategies such as specialized capsules, permeation enhancers, and next-generation peptide engineering including sequence optimization and fatty-acid conjugation to improve GI stability and absorption. Investments are also growing in small-molecule GLP-1 agonists as an alternative path, alongside lipid-based formulations and permeation enhancers like SNAC that are enabling clinically useful oral bioavailability.
Read the full report for deeper insights into the evolving GLP-1 landscape (Page 32).
As GLP-1 therapies shift from injectable to oral dosage forms, overcoming bioavailability and solubility challenges has become a central development priority. Emerging onto the scene are strategies such as specialized capsules, permeation enhancers, and next-generation peptide engineering including sequence optimization and fatty-acid conjugation to improve GI stability and absorption. Investments are also growing in small-molecule GLP-1 agonists as an alternative path, alongside lipid-based formulations and permeation enhancers like SNAC that are enabling clinically useful oral bioavailability.
Read the full report for deeper insights into the evolving GLP-1 landscape (Page 32).
Share article
Related Content